

UNIVERSITÉ  
PARIS-SUD 11

# **MURINE MODELS FOR EVALUATING THE ALLERGENICITY OF GENETICALLY MODIFIED FOODS**

---

**Hatice Aldemir, Ph.D**

**University of Paris XI**

**ILSI New Methods Workshop**

**23-25 October 2007**

**Nice – France.**

# Plan

---

- Critical parameters of animal models
- Mouse models
  - Literature review
  - ILSI ring trial (2005)
  - Syngenta-Bayer CS Collaborative work
  - A new promising mouse model
- Conclusion

# Plan

---

- **Critical parameters of animal models**
- **Mouse models**
  - Literature review
  - ILSI ring trial (2005)
  - Syngenta-Bayer CS Collaborative work
  - A new promising mouse model
- **Conclusion**

# **Critical parameters for establishing a robust, cost effective and reproducible animal model**

---

- \* **Animals**
  - Strain, age, sex, exposure to food, etc.
- \* **Test material:**
  - Allergens and non-allergens
  - Determination of matrix effect: pure protein vs. whole plant
  - Effects of food processing or digestion
  - Presence of adjuvants: modified immune responses
- \* **Experimental design:**
  - Route of administration (iv, ip, oral, td, etc.)
  - Frequency and dose of administration: graded allergenicity
- \* **Biomarkers: IgE, IgG, cytokines, cell surface markers, etc.**
- \* **Reliability of the model: inter-laboratory comparisons**
- \* **Relevance to human data: (e.g. Active Systemic Anaphylaxis)**

# Plan

---


- Critical parameters of animal models
- Mouse models
  - Literature review
  - ILSI ring trial (2005)
  - Syngenta-Bayer CS Collaborative work
  - A new promising mouse model
- Conclusion

# **MOUSE MODELS OF FOOD ALLERGY**


---

- **X-M. Li et al. 2000 (Oral, Peanut)**
- **K. Adel-Patient et al. 2000 (I.P., Milk)**
- **R. Dearman et al. 2003 (I.P., OVA, BSA, PNA, STA, PAP)**
- **V. Morafo et al. 2003 (I.G., CM, PNA)**
- **C.J. Betts et al. 2004 (I.D., PNA & STA)**
- **F. vanWijk et al. 2004 (Oral, Peanut)**
- **S-Y. Lee et al. 2005 (I.G., Buckwheat)**
- **N. Birmingham et al. 2005 & 2007 (I.P. and T.D. , Hazelnut)**
- **K. Vaali et al. 2006 (T.D., OVA)**
- **Gizzarelli et al. 2006 (I.G., WT and GM-Soybean)**
- **etc...**

# Oral gavage sensitisation models




# Oral gavage sensitisation models (continued)





Morafo et al.  
2003

Adel-Patient et al.  
2005




Gizzarelli et al.  
2006


# Dermal & Intra-dermal sensitisation models



Vaali et al.  
2006  
Transdermal





Betts et al.  
2004  
Intra-dermal





Birmingham et al.  
2005 & 2007  
Transdermal



# I.P. sensitisation models



Birmingham et al.  
2005



Adel-Patient et al.  
2000



Dearman et al.  
2003

# Conclusion

---

- **Many different models developed**
- **All based on IgE detection**
- **Adjuvant necessary for oral sensitisation**
- **Limited number of allergens and non-allergens tested**

# Plan

---

- Critical parameters of animal models
- Mouse models
  - Literature review
  - ILSI ring trial (2005)
  - Syngenta-Bayer CS Collaborative work
  - A new promising mouse model
- Conclusion

# ILSI ring trial

---

## Animal models

IP; no adjuvant; BALB/c

IP; no adjuvant; BALB/c, A/J, C3H

IP; no adjuvant; BALB/c

IP; +/- adjuvant; BALB/c, A/J, C3H, C57BL6

IP; +/- adjuvant; BALB/c

## Laboratories

Bayer CropScience

Dupont

Syngenta

Monsanto

Dow

## Test Proteins

Ara h 1 (peanut allergen)

Ara h 2 (peanut allergen)

B-lactoglobulin (cows' milk allergen)

Rubisco (non-allergen)

Soy lipoxygenase (non-allergen)

# **ILSI ring trial**

---

## **Endpoints measured:**


Clinical scoring      => Active Systemic Anaphylaxis (ASA)

IgG levels                => ELISA

IgE levels                => Passive Cutaneous Anaphylaxis (PCA)


# Passive Cutaneous Anaphylaxis (PCA)

## Phase I: Sensitisation



# Passive Cutaneous Anaphylaxis (PCA) Phase II: Elicitation

---



Mouse  
Tail

*Hatice Aldemir*

# PCA (continued)

Ear of a naïve mouse


IgE Receptor

Mast cell

IgE


Serum from  
sensitised mouse  
e.g. PNA

48h after  
PNA +  
Evans Blue






# Passive Cutaneous Anaphylaxis (PCA)

## Phase II: Elicitation





# BCS Results

## STRONG HUMAN ALLERGENS



## WEAK HUMAN ALLERGENS



But high LPS contamination and potential cross-reactivity!

# Combined Results

Protein	Lab A		Lab B		Lab C		Lab D
	Sensitize days 1, 7, 14 IgG => ELISA IgE => PCA d21		Sensitize days 1, 7 IgG => ELISA IgE => PCA d14		Sensitize days 0, 7, 28 IgE => het. PCA day 28 Clinical Symptoms d45		Sensitize days 1, 7 IgG =>ELISA IgE => PCA d14
	BALB/c	BDF1	C3H/HeJ	BDF1	A/J	C3H/HeJ	BALB/c
Ara h1	(+) specific IgE	(+) specific IgE	Not examined.	Not examined.	Positive Clinical Score	Positive Clinical Score	(+) specific IgG and IgE
Ara h2	(-) specific IgG and IgE	(-) specific IgG and IgE	Not examined.	Not examined.	Positive Clinical Score	Positive Clinical Score	(-) specific IgG
β-lacto-globulin	(-) specific IgE	(-) specific IgE	Not examined.	(+) specific IgG and IgE	Negative Clinical Score	Negative Clinical Score	(+) specific IgG and IgE
Rubisco	(+) specific IgE	(+) specific IgE	(+) specific IgG and IgE	Not examined.	Negative Clinical Score	Negative Clinical Score	(+) specific IgG and IgE
Soybean Lipo-oxygenase	(+) specific IgE	(+) specific IgE	(+) specific IgG and IgE	Not examined.	Positive Clinical Score	Positive Clinical Score	(+) specific IgG and IgE

EVALUATION OF IP MOUSE MODELS FOR ASSESSING THE ALLERGENIC POTENTIAL OF PROTEINS. Thomas, K., Hérouet, C., Bannon, G., Ladics, G., MacIntosh, S., Privalle, L., Woolhiser, M., Hefle, S. ILSI, Bayer CropScience, Monsanto, Dupont Co., Bayer Bioscience, BASF, The Dow Chemical Company, University of Nebraska. AAAAI Congress, San Antonio, 2005.

# ILSI ring trial: Conclusion

---


- Difficult to differentiate between allergens and non-allergens consistently with various models.
- Adequate purification (e.g. LPS) and good characterization of proteins are important.
- The mechanisms of action for each protein (allergy *vs.* tolerance) need to be explored.

# Plan

---

- Critical parameters of animal models
- Mouse models
  - Literature review
  - ILSI ring trial (2005)
  - Syngenta-Bayer CS Collaborative work
  - A new promising mouse model
- Conclusion

# R.J. Dearman et al. => Intraperitoneal sensitisation model 2003




8-12-w-old

BALB/c




Ovalbumin  
Peanut agglutinin  
Potato agglutinin




# Results: Phase I

2003


## Serum levels of specific-IgG ■ and IgG1 ●



**PNA 0.1%**  
**Peanut**



**2% OVA**  
**Egg**




**5% STA**  
**Potato**


# Results: Phase I

2003


## Serum levels of specific IgE



**PNA 0.1%**  
**Peanut**




**2% OVA**  
**Egg**



**5% STA**  
**Potato**

# Apparent spectrum based on IgE levels

---



# Conclusions: Phase I

2003


---

- => Measurement of IgE responses by PCA in BALB/c mice appears to accurately identify allergens.
- => This model is relatively robust and can be transferred successfully between laboratories.

# Results: Phase II

2007

## IgE levels



=> Confirmation of the strength and repeatability of the model.

=> The model needs to be standardized by testing more proteins.

# Plan


---

- Critical parameters of animal models
- Mouse models
  - Literature review
  - ILSI ring trial (2005)
  - Syngenta-Bayer CS Collaborative work
  - A new promising mouse model
- Conclusion


# Aim

---

## A new model of food allergy



# Sensitisation protocol




Different concentrations of Ara h 1, PAP or PNA were tested.

## Protein Concentrations

- 0.01 g/l (0.0025 mg/mouse)**
- 0.04 g/l (0.01 mg/mouse)**
- 0.16 g/l (0.04 mg/mouse)**
- 0.64 g/l (0.16 mg/mouse)**
- 2.50 g/l (0.64 mg/mouse)**

# The parameters: Tim-1, IL-5/IFN- $\gamma$ , IgE



Early

Intermediate

Late


# Late Marker => Protein-specific IgE (ELISA)

Protein-specific IgE levels


Arah1

Pap


PNA



# Splenocyte culture for cytokine expression




# Intermediate Markers => IL-5 / IFN- $\gamma$ Ratio




# Early marker => Surface Tim-1 expression


Control-Arah1




Allergen Ara h 1



Control-PAP




Non-Allergen PAP



Tim-1 surface expression


# The parameters: Tim-1, IL-5 / IFN- $\gamma$ , IgE



# New model: Conclusion

---

This animal model with the selected parameters is promising to discriminate between



**Strong Allergen**

**Weak allergen**

However: Standardisation of the model is necessary

# General Conclusion

---

=> Standardisation / International validation

Need for more proteins to be tested

=> Several animal models are needed

* <u>Clinical model</u>	vs.	<u>Mechanistic model</u>
ASA scoring		IgE, IgGs, cytokines, etc.
* <u>Protein</u>	vs.	<u>Food</u>
Purity & conformation		Matrix & Processing

=> Weigh of evidence approach (*Codex Alimentarius 2003*)

**Thank you very much  
for your kind attention.**

---



# Sponsored by

## Bayer CropScience

---

**Special thanks to:**

**Dr. C. Herouet-Guicheney (BCS)**

**Dr. R. Bars (BCS)**

**Prof. M. Pallardy (Univ. Paris XI)**

**Prof. N. Glaichenhaus (Univ. Nice)**

**BCS participants to the work**

**Dr. de Barbeyrac**


**Dr. P. Kennel**

**Dr. D. Rouquié**


**BCS Zootech & Technical Groups**

# Late Marker => Protein-specific IgG


Ara h1




PAP




Peanut Lectin




RUBISCO




# Molecular mechanism of allergy



# ELISA (Igs, Cytokines, etc..)




# Cytometric Bead Array (CBA)



# Analysis of cytokines by Cytometric Bead Array (CBA)

Color of the beads



Fluorescence Intensity

=

Quantity of cytokine




Becton Dickinson (BD)


FACS  
In CNRS Lab.

# CD4 => T helper cell marker

Total splenocytes  
are analysed  
according to size  
and granularity




Total splenocytes




Non-stained cells

T helper cells are  
marked with the  
specific antibody  
CD4-FITC



T helper marker-stained cells



Non-Th cells

T helper cells

# Endotoxins (Endotoxin Units / mg protein)

